The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10858 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial drugs

Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?

September 28, 2011 - 06:54 -- Kabogo Ndegwa
Author(s): 
Colinn J. Sutherland, Hamza Babiker, Margaret J. Mackinnon, Lisa Ranford-Cartwright, Badria Babiker El Sayed
Reference: 
Parasitology, Volume 138, Special Issue 12 - Symposia of the British Society for Parasitology Volume 47, October 2011, pp 1459 – 1468

Artemisinin-based combination therapy is exerting novel selective pressure upon populations of Plasmodium falciparum across Africa.

Person: 
Continent: 
Medical Condition: 
Medical Treatment: 

Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression

September 15, 2011 - 14:21 -- Patrick Sampao
Author(s): 
Hervé Le Nagard, Corine Vincent, France Mentré, Jacques Le Bras
Reference: 
Computer Methods and Programs in Biomedicine, Volume 104, Issue 1

We proposed an approach based on the inhibitory sigmoid Emax model, which is often used in pharmacology, with estimation of IC50 through nonlinear regression using a standard function of the R software.

Technology: 
Medical Treatment: 

Challenges in antimalarial drug discovery

September 8, 2011 - 06:40 -- Kabogo Ndegwa
Author(s): 
Jeremy N Burrows, Didier Leroy, Julie Lotharius, David Waterson
Reference: 
Future Medicinal Chemistry, September 2011, Vol. 3, No. 11, Pages 1401-1412

Malaria is one of the most devastating diseases in the world, affecting almost 225 million people a year, and causing over 780,000 deaths, most of which are children under the age of 5 years.

Medical Treatment: 

Open Access | Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

August 30, 2011 - 11:32 -- Kabogo Ndegwa
Author(s): 
Khalil IF, Alifrangis M, Recke C, Hoegberg LC, Ronn A, Bygbjerg IC, Koch C
Reference: 
Malaria Journal 2011, 10:249 (24 August 2011)

The developed ELISA can be used for quality screening of CQ in pharmaceutical formulations and for drug monitoring in malaria and in other infectious diseases, such as HIV, where CQ proved to be an effective therapeutic agent.

Medical Condition: 
Medical Treatment: 

Open Access | Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine

August 24, 2011 - 09:24 -- Kabogo Ndegwa
Author(s): 
Kritsiriwuthinan K, Chaotheing S, Shaw PJ, Wongsombat C, Chavalitshewinkoon-Petmitr P, Kamchonwongpaisan S
Reference: 
Malaria Journal 2011, 10:242 (18 August 2011)

The malaria parasite's molecular responses to PN and CQ treatment are similar in terms of the genes and pathways affected.

Medical Condition: 
Medical Treatment: 

Open Access | Phenotypic Screens, Chemical Genomics, and Antimalarial Lead Discovery

August 24, 2011 - 09:17 -- Kabogo Ndegwa
Author(s): 
Jose F. Garcia-Bustos, Francisco-Javier Gamo
Reference: 
PLoS Pathog 7(8): e1002156

Several extensive small molecule screens against growing Plasmodium falciparum have recently been published [1]–[3] and thousands of hit structures are now publicly available.

Medical Condition: 
Medical Treatment: 

Open Access | Plasmodium falciparum Metacaspase PfMCA-1 Triggers a z-VAD-fmk Inhibitable Protease to Promote Cell Death

August 24, 2011 - 09:14 -- Kabogo Ndegwa
Author(s): 
Benoît Meslin, Abdoul H. Beavogui, Nicolas Fasel, Stéphane Picot
Reference: 
PLoS ONE 6(8): e23867

Activation of proteolytic cell death pathways may circumvent drug resistance in deadly protozoan parasites such as Plasmodium falciparum and Leishmania.

Medical Treatment: 

Open Access | Antimalarial Activity of Potential Inhibitors of Plasmodium falciparum Lactate Dehydrogenase Enzyme Selected by Docking Studies

July 25, 2011 - 08:36 -- Kabogo Ndegwa
Author(s): 
Julia Penna-Coutinho, Wilian Augusto Cortopassi, Aline Alves Oliveira, Tanos Celmar Costa França, Antoniana Ursine Krettli
Reference: 
PLoS ONE 6(7): e21237

The Plasmodium falciparum lactate dehydrogenase enzyme (PfLDH) has been considered as a potential molecular target for antimalarials due to this parasite's dependence on glycolysis for energy production.

Medical Condition: 
Medical Treatment: 

Open Access | Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria

July 5, 2011 - 08:04 -- Kabogo Ndegwa
Author(s): 
Jamsen KM, Duffull SB, Tarning J, Lindegardh N, White NJ, Simpson JA
Reference: 
Malaria Journal 2011, 10:181 (1 July 2011)

The proposed sampling designs in this paper are robust and efficient and should be considered in future PK studies of oral artesunate where only three or four blood samples can be collected.

Medical Condition: 
Medical Treatment: 

Molecular Mechanism of Renal Tubular Secretion of the Antimalarial Drug Chloroquine

June 21, 2011 - 06:47 -- Kabogo Ndegwa
Author(s): 
Fabian Müller, Jörg König, Hartmut Glaeser, Ingrid Schmidt, Oliver Zolk, Martin F. Fromm, and Renke Maas
Reference: 
Antimicrobial Agents and Chemotherapy, July 2011,p. 3091-3098, Vol. 55, No. 7

The antimalarial drug chloroquine is eliminated to a significant extent by renal tubular secretion.

Medical Treatment: 

Pages

Subscribe to RSS - antimalarial drugs